T. Rowe Price Associates
KNSA icon

T. Rowe Price Associates’s Kiniksa Pharmaceuticals KNSA Stock Holding History

T. Rowe Price Associates’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
+34,830
New +$1.81M ﹤0.01% 1951
2025
Q2 		– Sell
-16,755
Closed -$373K – 3104
2025
Q1 		$373K Buy
16,755
+1,644
+11% +$33.8K ﹤0.01% 2375
2024
Q4 		$299K Buy
15,111
+2,881
+24% +$65.8K ﹤0.01% 2513
2024
Q3 		$306K Buy
12,230
+348
+3% +$8.48K ﹤0.01% 2467
2024
Q2 		$222K Buy
+11,882
New +$223K ﹤0.01% 2553
2021
Q3 		– Sell
-13,231
Closed -$184K – 2966
2021
Q2 		$184K Buy
+13,231
New +$201K ﹤0.01% 2749

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

T. Rowe Price Associates's KNSA Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 34,830 shares worth $2.23M. The stake represents ﹤0.01% of the portfolio and ranks #1951 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in KNSA as recently as Q1 2025.

T. Rowe Price Associates first reported a position in KNSA in Q2 2021 and has held it in 6 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • T. Rowe Price Associates held 34,830 shares of Kiniksa Pharmaceuticals worth $2.23M as of Q2 2026.
  • Kiniksa Pharmaceuticals was a new T. Rowe Price Associates position in Q2 2026.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1951 holding.
  • T. Rowe Price Associates first reported a position in Kiniksa Pharmaceuticals in Q2 2021 and has held it in 6 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.